Aspen Neuroscience
United States
21 articles about Aspen Neuroscience
-
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson's Disease
4/17/2024
Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD).
-
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
2/14/2024
Aspen Neuroscience, Inc. announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
-
Aspen Neuroscience Appoints Ana Sousa Chief Regulatory Officer
1/16/2024
Aspen Neuroscience, Inc. announced the appointment of Ana Sousa, MSJ as the company's Chief Regulatory Officer.
-
Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
11/21/2023
Biocom California, the association representing the California life sciences industry, has announced that Andrés Bratt-Leal, PhD, Aspen Neuroscience co-founder and senior vice-president of research and development, is a recipient of the 2023 Life Science Catalyst Awards.
-
Aspen Neuroscience to Present at 2023 Cell & Gene Meeting on the Mesa
10/9/2023
Aspen Neuroscience announced today that Chief Technology Officer Kim Raineri and Chief Scientific Officer Xiaokui Zhang, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa, held this week in Carlsbad, Calif. and live-streamed globally.
-
Aspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study
8/24/2023
Aspen Neuroscience announced that it is partnering with Emerald Innovations, a pioneer in the creation of "invisible" off-body sensors for measuring health analytics, and Rune Labs, a software and data analytics company for precision neurology, to incorporate digital health modalities in the company's Trial-Ready Screening Cohort Study.
-
Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson's Disease
8/8/2023
Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001.
-
Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona
6/29/2023
Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain , Aspen Neuroscience co-founder Andres Bratt-Leal , PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001.
-
Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions
6/14/2023
Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present "Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics," during the Focus Sessions taking place during this week's 2023 International Society for Stem Cell Research Annual Meeting in Boston, Mass.
-
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
12/21/2022
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson's disease, has signed a $40 million credit facility with Silicon Valley Bank.
-
CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer
10/19/2022
Aspen Neuroscience, Inc. announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company's executive team.
-
Dr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene Meeting on the Mesa
10/11/2022
This week Xiaokui Zhang , Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif.
-
NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting
6/22/2022
Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams , Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
-
Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson's Disease
4/11/2022
Aspen Neuroscience, Inc. announced that this month it will launch the first patient screening study of its kind.
-
Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer
11/18/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company's executive team.
-
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
11/9/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company's executive team.
-
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
7/13/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Ana Sousa has joined the company as senior vice president of regulatory affairs and quality, and as a member of the company's executive team.
-
Aspen Neuroscience Announces Promotion of Andres Bratt-Leal, PhD, to Senior Vice President of Research & Development
5/5/2021
Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Andres Bratt-Leal, PhD, has been promoted to Senior Vice President of Research & Development.